CHICAGO—Adding cetuximab to first-line irinotecan chemotherapy for patients with metastatic colorectal cancer gave a median four months advantage in overall survival as compared with adding bevacizumab. Findings from the German Phase III FIRE study were presented at the 2013 meeting of the American Society of Clinical Oncology in Chicago by Professor Volker Heinemann from Munich University. He explained to Peter Goodwin why this research has clarified the clinical decision-making process for patients who have the non-mutated form of the KRAS gene and are thus sensitive to both of these targeted agents.
You may also like...
Initial Gleason score does not predict abiraterone response in patients with metastatic castration-resistant prostate cancer 12 Feb, 2014 ASCO Audio Journal of Oncology – September 1st, 2006 30 Aug, 2006 New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer 15 Dec, 2007 ASCO Audio Journal of Oncology in Advance – October 15th, 2006 14 Oct, 2006
- Previous story Patients with oropharyngeal cancer: no HPV risk to spouses, partners
- Next story Heat shock protein inhibitor brings new hope in advanced pre-treated lung cancer
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014